Joshua Qin

Joshua Qin has a diverse work experience in various industries. Starting from 2022, they have been working as the Sr. Director of Corporate Strategy & Finance at Vera Therapeutics, Inc. Prior to that, they held positions at Natera, where they worked in Global Business & Corporate Development from 2020 to 2022, and in Commercial Strategy from 2017 to 2020.

Before joining Natera, Joshua worked at Centerview Partners as a Healthcare M&A advisor from 2015 to 2017, where they provided guidance on M&A and partnership opportunities. At Symphony Technology Group, they worked in Private Equity from 2013 to 2015, where they built complex models, conducted due diligence, and facilitated various acquisitions.

Joshua also gained experience at Evercore Partners as an M&A professional, specializing in technology sectors such as software, mobile, and patents, from 2011 to 2013. Prior to that, they worked as a Summer Analyst in Investment Banking at Bank of America Merrill Lynch in 2010.

Additionally, Joshua had early work experiences as a Research Associate at ChronoWake in 2009 and as a Summer Analyst at CalPERS in 2008.

Joshua Qin has a Bachelor of Science degree in Economics with a focus on Finance, Operations, and Information Management from The Wharton School. Joshua also has a Bachelor of Arts degree in Neuroscience (formerly known as BBB) from the University of Pennsylvania. In addition to their degrees, Joshua Qin holds certifications in Series 63 and Series 79 from the Financial Industry Regulatory Authority (FINRA). However, specific information regarding the years of completion for both their education and certifications is not provided.